Glofitamab for aggressive B-cell lymphoma with biopsy-guided monitoring
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a drug called glofitamab for people with aggressive B-cell lymphomas (like DLBCL or mantle cell lymphoma) that have come back or not responded to standard treatments. The study uses a biopsy during treatment to see how the drug is working, aiming to make treatment more personalized.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of aggressive B-cell lymphoma, like DLBCL or mantle cell lymphoma.
- Your cancer must have gotten worse after at least one standard treatment.
- You need a lymphoma lump that can be safely biopsied with a needle, such as in the neck, armpit, groin, or under the skin.
- You cannot have had a stem cell or organ transplant in the past.
- You cannot have had previous treatment with a bispecific antibody that targets CD3 and CD20.
- You should be in generally good health, without serious heart disease, recent major surgery, or active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination therapy using glofitamab for people aged 65 or older with diffuse large B-cell lymphoma who have not received prior treatment. The goal is to see if this approach is safe and effective for patients who are considered too frail for standard therapies.
This study looks at how well a medicine called glofitamab works and how safe it is for people with a type of blood cancer (diffuse large B-cell lymphoma) that did not respond to first treatment or came back within a year. If you qualify, you may receive glofitamab as part of your care, and the study will track your progress.
This study looks at how well a new drug called glofitamab works in real life for people with a type of lymphoma that has come back or not improved after treatment. It aims to see if the drug is safe and effective outside of a clinical trial setting.
This trial tests a drug called glofitamab for people with a type of lymphoma (DLBCL) that has come back or not responded to at least two prior treatments. The goal is to see if this drug can help shrink tumors or stop the disease from progressing.
This study tests an extra treatment called glofitamab (given as an infusion) after your first therapy has worked well, to help keep the lymphoma from coming back. It is for people with high-risk large B-cell lymphoma, and aims to improve long-term remission.
This study tests two ways of giving a new drug called glofitamab — either alone or combined with chemotherapy (GemOx) — for people with aggressive B-cell lymphoma that has returned or not responded to previous treatment. The goal is to find a safer way to give the drug and to see if it helps control the cancer.
Hear when a new Relapsed/Refractory Diffuse Large B-Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.